tbuckley/cabot-search huggingface dataset:
United States Supreme Court and abortion. 3
Authors: E. J. Holman
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation
Authors: Tingting Weng, Junsuk Ko, Chioniso P. Masamha, Zheng Xia, Yu Xiang, Ning-yuan Chen, Jose G. Molina, Scott Collum, Tinne C. Mertens, Fayong Luo, Kemly Philip, Jonathan Davies, Jingjing Huang, Cory Wilson, Rajarajan A. Thandavarayan, Brian A. Bruckner, Soma S.K. Jyothula, Kelly A. Volcik, Lei Li, Leng Han, Wei Li, Shervin Assassi, Harry Karmouty-Quintana, Eric J. Wagner, Michael R. Blackburn
Journal: Journal of Clinical Investigation (2019)

Idiopathic pulmonary fibrosis (IPF) is a chronic and deadly disease with a poor prognosis and few treatment options. Pathological remodeling of the extracellular matrix (ECM) by myofibroblasts is a key factor that drives disease pathogenesis, although the underlying mechanisms remain unknown. Alternative polyadenylation (APA) has recently been shown to play a major role in cellular responses to stress by driving the expression of fibrotic factors and ECMs through altering microRNA sensitivity, but a connection to IPF has not been established. Here, we demonstrate that CFIm25, a global regulator of APA, is down-regulated in the lungs of patients with IPF and mice with pulmonary fibrosis, with its expression selectively reduced in alpha-smooth muscle actin (α-SMA) positive fibroblasts. Following the knockdown of CFIm25 in normal human lung fibroblasts, we identified 808 genes with shortened 3'UTRs, including those involved in the transforming growth factor-β signaling pathway, the Wnt signaling pathway, and cancer pathways. The expression of key pro-fibrotic factors can be suppressed by CFIm25 overexpression in IPF fibroblasts. Finally, we demonstrate that deletion of CFIm25 in fibroblasts or myofibroblast precursors using either the Col1a1 or the Foxd1 promoter enhances pulmonary fibrosis after bleomycin exposure in mice. Taken together, our results identified CFIm25 down-regulation as a novel mechanism to elevate pro-fibrotic gene expression in pulmonary fibrosis.
SP0179 Ultrasound in Lung Fibrosis
Authors: L. Gargani
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Promising data have recently been obtained by lung ultrasound (LUS), which allows the detection of pulmonary fibrosis by the evaluation of B-lines (previously called ultrasound lung comets). B-lines are the sonographic sign of pulmonary interstitial involvement, including increased thickness of the pulmonary septa. Traditionally, B-lines have been employed in patients with heart failure to detect the location and quantification of extravascular lung water, but many data suggest their use also in assessing interstitial lung disease. Assessment of B-lines by LUS would represent an attractive biomarker for the frequent evaluation of pulmonary involvement in patients with rheumatic disease, since it is non-ionising, inexpensive and easy to perform and interpret. <h3>Image/graph</h3> <h3>Disclosure of Interest</h3> None Declared
Public Health Emergency Risk Communication and Social Media Reactions to an Errant Warning of a Ballistic Missile Threat — Hawaii, January 2018
Authors: Bhavini Patel Murthy, Nevin Krishna, Terrance Jones, Amy Wolkin, Rachel Nonkin Avchen, Sara J. Vagi
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

On January 13, 2018, at 8:07 a.m. Hawaii Standard Time, an errant emergency alert was sent to persons in Hawaii. An employee at the Hawaii Emergency Management Agency (EMA) sent the errant alert via the Wireless Emergency Alert (WEA) system and the Emergency Alert System (EAS) during a ballistic missile preparedness drill, advising persons to seek shelter from an incoming ballistic missile. WEA delivers location-based warnings to wireless carrier systems, and EAS sends alerts via television and radio (1). After 38 minutes, at 8:45 a.m., Hawaii EMA retracted the alert via WEA and EAS (2). To understand the impact of the alert, social media responses to the errant message were analyzed. Data were extracted from Twitter* using a Boolean search for tweets (Twitter postings) posted on January 13 regarding the false alert. Tweets were analyzed during two 38-minute periods: 1) early (8:07-8:45 a.m.), the elapsed time the errant alert circulated until the correction was issued and 2) late (8:46-9:24 a.m.), the same amount of elapsed time after issuance of the correction. A total of 5,880 tweets during the early period and 8,650 tweets during the late period met the search criteria. Four themes emerged during the early period: information processing, information sharing, authentication, and emotional reaction. During the late period, information sharing and emotional reaction themes persisted; denunciation, insufficient knowledge to act, and mistrust of authority also emerged as themes. Understanding public interpretation, sharing, and reaction to social media messages related to emergencies can inform development and dissemination of accurate public health messages to save lives during a crisis.
AB0443 Influence of the Reason for Discontinuation of Previous TNF Antagonists on the Retention of Tocilizumab
Authors: N. Asai, T. Kojima, A. Kaneko, Y. Yabe, T. Shioura, K. Saito, T. Kobayakawa, N. Ishiguro
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Tocilizumab (TCZ) is effective for rheumatoid arthritis (RA) patients with inadequate responses to tumor necrosis factor (TNF) antagonists. However, it has not yet been established whether the type of failure that motivated the switch from TNF antagonists influences the retention of TCZ. <h3>Objectives</h3> The present study was undertaken to investigate the relationship between the retention of TCZ and the reason for discontinuation of previous TNF antagonists in RA patients. <h3>Methods</h3> This study included 181 RA patients who switched from TNF antagonists to TCZ therapy in Tsurumai Biologics Communication Registry (TBCR). The continuation rates and causes of discontinuation of TCZ were compared between two groups divided by the reasons for discontinuation of previous TNF antagonists (142 patients with inefficacy and 25 patients with adverse events). <h3>Results</h3> The continuation rate of TCZ after 2 years in patients with inefficacy (76.8%) was significantly higher compared with patients with adverse events (56.0%). At the rate of discontinuation of TCZ due to inefficacy, no significance was shown between the two groups (9.2% vs 4.0%). On the other hand, the rate of discontinuation of TCZ due to adverse events in patients with inefficacy was significantly lower than patients with adverse events (6.3% vs 36.0%). <h3>Conclusions</h3> RA patients who switched from TNF antagonists due to inefficacy to TCZ have high rates of continuation. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2299
NHSX: Hancock sets up new policy unit to support technology in NHS
Authors: Gareth Iacobucci
Journal: BMJ (2019)

The government has announced the formation of a new policy unit specifically to support the use of technology in the NHS.

NHSX—a joint venture between the Department of Health and Social Care, NHS England, and NHS Improvement—will be charged with setting consistent national policy and developing best practice for technology, digital services, and data throughout the NHS.

Its remit will include establishing and mandating uniform standards for using technology, joining up IT systems across the …
Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies
Authors: Christopher C. Frohne, Ernesto M. Llano, Ashley Perkovic, Russell D. Cohen, Jason J. Luke
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Immune checkpoint inhibitors (ICPIs) are increasingly being used in the treatment of a variety of malignancies. The original studies that demonstrated the efficacy of ICPIs excluded patients actively being treated for autoimmune conditions, and there is only limited evidence that these treatments are safe and effective in this population of patients. <h3>Case presentation</h3> We present a case of a man with Crohn's disease actively requiring immunosuppressive therapy who subsequently received pembrolizumab for metastatic melanoma. He had no further progression of metastatic disease and had resolution of his pulmonary nodule while he experienced no Crohn's disease flares or immune related adverse events. We surveyed the existing literature for studies examining the use of ICPIs in patients with autoimmune disorders and reviewed the unique mechanism of action of the α4β7 inhibitor, vedolizumab. <h3>Conclusion</h3> Patients with autoimmune conditions should be considered candidates for immune checkpoint inhibition even in the setting of active immunosuppressive therapy. The mechanism of action of immunosuppressive therapy should be considered with the most targeted form of treatment being used when possible. Further prospective studies investigating immunotherapy in patients with autoimmune conditions are warranted.
Brentuximab vedotin is an effective therapy for CD30<sup>+</sup> mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost?
Authors: J.J. Scarisbrick
Journal: British Journal of Dermatology (2017)

Linked Article:Stranzenbach et al. Br J Dermatol 2017; 177:1503–1509.
A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease
Authors: Simona Sammassimo, Daniele Avenoso, Federica Gigli, Daniele Laszlo, Francesco Bertolini, Giammarco Russo, Corrado Tarella, Rocco Pastano
Journal: Blood (2018)
Multiple Cutaneous Nodules and Limb Swelling
Authors: Garima Dabas, Dipankar De, Bishan Das Radotra
Journal: JAMA Oncology (2019)

A man in his 30s with painless swelling of the left upper limb and nodules on the left side of the chest and abdomen developed edema in the left upper limb 20 days after examination. What is your diagnosis?
Elevated Expression of CC Chemokine Ligand 18 in Chronic Rhinosinusitis
Authors: A. Kato, S. Peterson, J.A. Poposki, D.R. Nagarkar, R.T. Chustz, A.T. Peters, L.A. Suh, R. Carter, J. Norton, K.E. Harris
Journal: Journal of Allergy and Clinical Immunology (2011)
A Logic-Gated Modular Nanovesicle Enables Programmable Drug Release for On-Demand Chemotherapy
Authors: Longguang Tang, Zhen Yang, Zijian Zhou, Ying Ma, Dale O. Kiesewetter, Zhantong Wang, Wenpei Fan, Shoujun Zhu, Mingru Zhang, Rui Tian, Lixin Lang, Gang Niu, Xianzhong Zhang, Xiaoyuan Chen
Journal: Theranostics (2019)

It remains a major challenge to achieve precise on-demand drug release.Here, we developed a modular nanomedicine integrated with logic-gated system enabling programmable drug release for on-demand chemotherapy.Methods: We employed two different logical AND gates consisting of four interrelated moieties to construct the nanovesicles, denoted as v-A-CED 2 , containing oxidation-responsive nanovesicles (v), radical generators (A), and Edman linker conjugated prodrugs (CED 2 ).The first AND logic gate is connected in parallel by mild hyperthermia (I) and acidic pH (II), which executes NIR laser triggered prodrug-to-drug transformation through Edman degradation.Meanwhile, the mild hyperthermia effect triggers alkyl radical generation (III) which contributes to internal oxidation and degradation of nanovesicles (IV).The second AND logic gate is therefore formed by the combination of I-IV to achieve programmable drug release by a single stimulus input NIR laser.The biodistribution of the nanovesicles was monitored by positron emission tomography (PET), photoacoustic, and fluorescence imaging.Results: The developed modular nanovesicles exhibited high tumor accumulation and effective anticancer effects both in vitro and in vivo.Conclusions: This study provides a novel paradigm of logic-gated programmable drug release system by a modular nanovesicle, which may shed light on innovation of anticancer agents and strategies.
Navigating the Fas lane to improved cellular therapy for cancer
Authors: Madhav V. Dhodapkar
Journal: Journal of Clinical Investigation (2019)

Genetically engineered T cells have shown promising activity in the treatment of cancer. However, these cells are also potentially susceptible to immune-suppressive pathways in the tumor microenvironment that may limit their efficacy. In this issue of the JCI, Yamamoto et al. describe a new cellular engineering approach to prevent Fas-mediated inhibition of T cell function, which may be exploited to improve cellular therapy for cancer.
Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Authors: Tianyu Cai, Roman Galetto, Agnès Gouble, Julianne Smith, Antonio Cavazos, Lina Han, Qi Zhang, Vinitha Mary Kuruvilla, Sergej Naumovich Konoplev, Sattva S. Neelapu, Andrew A. Lane, Monica L. Guzman, Hagop M. Kantarjian, Naveen Pemmaraju, Marina Konopleva
Journal: Blood (2017)
Abstract 1550: The effect of snail on cellular adhesion in prostate cancer cells
Authors: Corey L. Neal, Danielle Mckeithen, Valerie Odero-Marah
Journal: Cancer Research (2011)

Abstract PURPOSE: The purpose of the study is to determine the role of Snail transcription factor on cellular adhesion to fibronectin and collagen, in human prostate cancer cells. Adhesion of cells to one another or the extracellular matrix (ECM) is responsible for normal and abnormal cellular activity, such as cell migration, invasion, metastasis of tumor cells, and angiogenesis. Snail transcription factor induces epithelial-mesenchymal transition (EMT) in which epithelial cells loose expression of specific genes and acquire traits of mesenchymal genes. We hypothesized that Snail will lead to decreased cellular adhesion to fibronectin and collagen matrix, concomitant with increased cell migration. DESIGN METHODS: We stably overexpressed Snail in LNCaP (LNCaP-Snail) and ARCaP (ARCaP-Snail) prostate cancer cells, or stably knocked down Snail in C4-2 and ARCaP-Snail cells using shRNA. We performed cell adhesion and migration assays on fibronectin and collagen I matrices using these cell models. Flow cytometry was also used for integrin expression analysis. RESULTS: We found that ARCaP prostate cancer cells transfected with Snail displayed decreased adhesion to fibronectin and collagen I, which was reversed by Snail knockdown. Additionally we have seen a decrease in the expression of the α5 and α2 integrin among ARCaP cell lines over expressing Snail, concomitant with an increased migration in cell lines overexpressing Snail. CONCLUSION: We have shown that Snail decreases cell adhesion to fibronectin and collagen, and inversely increases cell migration. These studies define a new role for Snail transcription factor that may be crucial for cell detachment and subsequent metastasis. Supported by grants P20MD002285-01 &amp; G12RR003062-22 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1550. doi:10.1158/1538-7445.AM2011-1550
Digital CBT Reduces Insomnia Symptoms Round the Clock
Authors: Anita Slomski
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
Authors: Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara
Journal: Journal for ImmunoTherapy of Cancer (2019)

Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood.Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to May 2018 were enrolled in this study. PD-L1 expression in tumor cells (TC) and mismatch repair (MMR) were analyzed by immunohistochemistry. Epstein-Barr virus (EBV) was detected by in situ hybridization. Cancer genome alterations were evaluated by a next-generation sequencing-based panel. High tumor mutation burden (TMB) was defined as more than 10 mutations/megabase.A total of 80 pts were analyzed in this study. Tumor response was evaluated in 72 pts with measurable lesions and 14 pts (19%) had an objective response. Overall response rate (ORR) was significantly higher in pts with ECOGPS 0 in those with PS 1 or 2, MMR-deficient (MMR-D) in those with MMR-proficient (MMR-P), PD-L1+ in TC in those with PD-L1- in TC and PIK3CA mutation in those with PIK3CA wild-type. ORR was 31% in pts with at least one of the following factors; MMR-D, high TMB, EBV+ and PD-L1+ in TC vs. 0% in those without these factors. Progression-free survival was significantly longer in pts with PS 0 than in those with PS 1 or 2, MMR-D than in those with MMR-P, and PD-L1+ in TC than in those with PD-L1- in TC.Some features were associated with favorable response to nivolumab for AGC. Combining these features might be useful to predict efficacy.
Takotsubo Recurrence
Authors: Ken Kato, Davide Di Vece, Victoria L. Cammann, Jozef Micek, Konrad A. Szawan, Beatrice Bacchi, Thomas F. Lüscher, Frank Ruschitzka, Jelena R. Ghadri, Christian Templin
Journal: Journal of the American College of Cardiology (2019)
SP0016 How to Distinguish Normal from Abnormal Findings
Authors: D. Kane
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Ultrasound is a highly sensitive tool in demonstrating high definition structural changes in soft tissues such as synovium, tendons and muscle and in bone and cartilage. Multiple studies have confirmed that ultrasound is more sensitive than clinical examination in the detection of synovial inflammation and joint effusion in both small and large joints and also in the detection of tendonitis, tenosynovitis and enthesitis. Ultrasound findings have better interobserver reproducibility than clinical examination findings and have been validated by correlation with MRI, CT scintigraphy and histological techniques. These finding have been reproduced in patients with both early and late disease and by researchers of different levels of expertise and using equipment of varying technological standards. However gray scale and power Doppler ultrasound abnormalities of joint and soft tissues have been noted in normal asymptomatic populations and in patients with disease who meet remission criteria, leading to concerns as to how to distinguish normal from abnormal ultrasound findings. This lecture reviews the OMERACT definitions of ultrasound pathology, how they were defined and how effective they are in defining abnormality in clinical practice. The relevance of abnormal ultrasound findings in asymptomatic and remission populations in terms of prognosis and outcome is examined. The effect of ageing on ultrasound findings in joints of normal subjects is presented. <h3>Disclosure of Interest</h3> None Declared
The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis
Authors: Wajahat Z. Mehal, Rohit Loomba
Journal: Hepatology (2019)

Mehal, Wajahat Z. M.D., D.Phil.; Loomba, Rohit M.D., M.H.Sc.Editor(s): Corey, Kathleen E.5; Malhi, Harmeet6 Author Information
Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry
Authors: Daniel E. Carvajal-Hausdorf, Jonathan Patsenker, Kelly P. Stanton, Franz Villarroel-Espindola, Amanda Esch, Ruth R. Montgomery, Amanda Psyrri, Konstantine T. Kalogeras, Vassiliki Kotoula, George Foutzilas, Kurt A. Schalper, Yuval Kluger, David L. Rimm
Journal: Clinical Cancer Research (2019)

Imaging mass cytometry (IMC) uses metal-conjugated antibodies to provide multidimensional, objective measurement of protein targets. We used this high-throughput platform to perform an 18-plex assessment of HER2 ICD/ECD, cytotoxic T-cell infiltration and other structural and signaling proteins in a cohort of patients treated with trastuzumab to discover associations with trastuzumab benefit.An antibody panel for detection of 18 targets (pan-cytokeratin, HER2 ICD, HER2 ECD, CD8, vimentin, cytokeratin 7, β-catenin, HER3, MET, EGFR, ERK 1-2, MEK 1-2, PTEN, PI3K p110 α, Akt, mTOR, Ki67, and Histone H3) was used with a selection of trastuzumab-treated patients from the Hellenic Cooperative Oncology Group 10/05 trial (n = 180), and identified a case-control series.Patients that recurred after adjuvant treatment with trastuzumab trended toward a decreased fraction of HER2 ECD pixels over threshold compared with cases without recurrence (P = 0.057). After exclusion of the lowest HER2 expressers, 5-year recurrence events were associated with reduced total extracellular domain (ECD)/intracellular domain (ICD) ratio intensity in tumor (P = 0.044). These observations are consistent with our previous work using quantitative immunofluorescence, but represent the proof on identical cell content. We also describe the association of the ECD of HER2 with CD8 T-cell infiltration on the same slide.The proximity of CD8 cells as a function of the expression of the ECD of HER2 provides further evidence for the role of the immune system in the mechanism of action of trastuzumab.